About Pharma IPR Conference

Nearly $236 billion in global drug sales faces patent expiry by 2030, one of the largest patent cliffs the pharmaceutical industry has ever faced. At the same time, new small-molecule chemistry, novel formulations and complex biologics are reaching the market, and generics and biosimilars are growing worldwide. Managing IP across many markets has become a business-critical skill.

India is at the centre of this shift. Decades of process-chemistry strength, growing capability in biologics and advanced therapies, supportive national policy and venture capital have turned India from a manufacturing base into a mature innovation ecosystem. India-origin pharmaceutical patent families have grown more than four-fold in a decade, and India now accounts for nearly 10% of global pharmaceutical patents. Indian companies are securing high-value protection at the USPTO and EPO. They are also using TRIPS flexibilities to open generic and biosimilar routes into Latin America, Southeast Asia and Africa.

The same forces are reshaping IP far beyond pharma. Several things are making India a global IP hub across sectors; AI, semiconductors, mobility and green technologies are converging. Reforms such as the Patents (Amendment) Rules of 2024 and 2025, expedited examination, and incentives for startups and MSMEs have matured the framework. Global capability centres (GCCs) and academic technology transfer are expanding.

Informa Markets’ 16th Annual Pharma IPR India Conference co located with the 3rd Edition of India IP conclave brings both conversations under one roof. Over three days, in-house IP leaders, litigators, regulators and policymakers from US, UK/ EU, India, Asia (China & Japan) and Emerging markets including Brazil, Mexico, South Africa, and more come together. The programme runs as expert-led sessions, panel discussions and strategic case studies, structured as two tracks with shared themes